UK markets closed

Onconetix, Inc. (J4T.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.0940-0.0090 (-8.74%)
As of 03:29PM CEST. Market open.

Onconetix, Inc.

201 East Fifth Street
Suite 1900
Cincinnati, OH 45202
United States
513 620 4101
https://onconetix.gcs-web.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees12

Key executives

NameTitlePayExercisedYear born
Mr. Bruce HarmonChief Financial Officer325.01kN/A1958
Dr. Ralph Schiess Ph.D.Interim CEO & Chief Science OfficerN/AN/A1979
Dr. Brian Price Ph.D.Head of Technology Strategy117.66kN/AN/A
Mr. Frank A. Jaeger M.A., M.B.A.Senior VP of Marketing & Business DevelopmentN/AN/A1970
Mr. Andrew D. Skibo Ph.D.Global Head of Biologics OperationsN/AN/AN/A
Mr. Theodore Scott YohoHead of Business DevelopmentN/AN/AN/A
Dr. Ali I. Fattom Ph.D.Head of Science & DiscoveryN/AN/AN/A
Dr. Jay Newmark M.B.A., M.D.Chief Medical OfficerN/AN/AN/A
Mr. Christian BruhlmannChief Strategy Officer & GM of EuropeN/AN/A1977
Dr. Donald L. Very Jr., Ph.D.Senior VP of Commercial Research & DevelopmentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Corporate governance

Onconetix, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.